Prognose

Analytikernes gennemsnitlige kursmål er 19,18 € (+97,33 %). Medianen er 17,77 € (+82,82 %).

Køb	10
Behold	2
Sælg	0

Nyheder Til nyhedsfeedet

Immunic reduces supervisory board after resignation of Duane Nash

Dr. Duane Nash resigned from Immunic’s supervisory board effective September 10, 2026. The company said the resignation was not related to any disagreements over the company’s operations, policies or practices. As a result of his departure, the number of supervisory board members will be reduced from ten to nine; the notice is based on a Form 8‑K filed with the SEC. » Mere på de.investing.com
Immunic appoints Elena Ridloff to the board of directors

Immunic has appointed Elena Ridloff to the board of directors with immediate effect. Ridloff brings more than 20 years of experience in finance, corporate development and capital markets in the biopharma industry, currently serving as CFO of Sionna Therapeutics and as a board member at Kymera Therapeutics. The appointment comes ahead of the expected top-line data from the phase-3 trials of Vidofludimus-Calcium in relapsing multiple sclerosis and before the planned initiation of a confirmatory phase-3 program for progressive MS. » Mere på de.investing.com
Immunic appoints former Genentech exec Erik Lundgren as CEO

Immunic named Erik Lundgren CEO effective May 22, 2026, with his employment starting June 1; he succeeds Daniel Vitt who will remain on the board and continue to oversee scientific strategy and portfolio advancement. Lundgren brings nearly two decades of commercial and multiple sclerosis experience from Genentech and Roche, including work on the launch of Ocrevus. He will lead advancement of vidofludimus calcium through the pivotal phase 3 ENSURE trial in relapsing MS, a planned phase 3 program in primary progressive MS, and preparations for regulatory filings and potential commercialization. The company granted Lundgren an equity option to purchase 1 million shares under its 2026 inducement plan. » Mere på finance.yahoo.com

Virksomhedstal

I det seneste kvartal havde Immunic en omsætning på 0 € og et nettoresultat på -29,88 mio. €

(EUR)	juni 2026	YoY
Omsætning	0	-
Bruttofortjeneste	0	-
Nettoresultat	-29,88 mio.	31,30 %
EBITDA	-29,79 mio.	31,13 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	134,82 mio. €
Antal aktier	13,62 mio.
Højeste/laveste i 52 uger	15,11 € - 4,39 €
Udbytte	Nej
Beta	1,41
P/E (PE Ratio)	-2,38
PEG (PEG Ratio)	-0,03
K/I (PB Ratio)	3,81
P/S (PS Ratio)	0,00

Virksomhedsprofil

Immunic, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt eine Pipeline selektiver oraler immunologischer Therapien zur Behandlung chronischer Entzündungs- und Autoimmunerkrankungen. Sein führendes Entwicklungsprogramm ist IMU-838, das sich in der klinischen Phase 2 zur Behandlung von schubförmig remittierender Multipler Sklerose, entzündlichen Darmerkrankungen und anderen chronischen Entzündungs- und Autoimmunerkrankungen sowie zur Behandlung von Coronaviruserkrankungen befindet. Das Unternehmen entwickelt außerdem IMU-935, einen inversen Agonisten von ROR?t, und IMU-856 zur Wiederherstellung der Darmbarrierefunktion bei Patienten, die an Krankheiten wie entzündlichen Darmerkrankungen, Reizdarmsyndrom mit Durchfall, durch Immun-Checkpoint-Inhibitoren ausgelöster Kolitis und anderen Erkrankungen der Darmbarrierefunktion leiden. Der Hauptsitz von Immunic, Inc. befindet sich in New York, New York.

Navn	Immunic
CEO	Erik Lundgren
Hjemsted	New York City, ny USA
Websted	immunic-therapeutics.com
Sektor	Sundhed
Branche	Bioteknologi
Børsnotering	17.04.2014
Medarbejdere	100